Le Lézard
Classified in: Health, Science and technology
Subjects: Product/Service, Share Issue

Arcus Biosciences Announces New Employment Inducement Grants


Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted five new employees options to purchase a total of 21,200 shares of the Company's common stock at an exercise price per share of $19.50, which was the closing price on July 24, 2023, and restricted stock units to acquire a total of 10,600 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 A2a/A2b receptors) and HIF-2?. For more information about Arcus Biosciences' clinical and preclinical programs, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences


These press releases may also interest you

at 20:00
Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid Tumors
Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today that China National Medical Products Administration (NMPA) has...

at 18:45
SHATTERPROOF AND ANTHEM BLUE CROSS AND BLUE SHIELD FOUNDATION PARTNER TO REDUCE HEALTHCARE STIGMA AROUND A SUBSTANCE USE DISORDER
A substance use disorder (SUD) is a complex and often stigmatized health condition that affects countless individuals, families and communities. Stigma against people with a SUD extends beyond individual and interpersonal levels. The Shatterproof...

at 18:35
AARP Responds to 2024 Medicare and Social Security Trustees Reports
AARP CEO Jo Ann Jenkins issued the following statement in response to the Medicare and Social Security Trustees Reports released today:...

at 18:35
NUTEX HEALTH ANNOUNCES INTERNET AVAILABILITY OF PROXY MATERIALS FOR ITS 2024 ANNUAL MEETING
Nutex Health Inc. ("Nutex Health" or the "Company") , a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 9 states and primary care-centric, risk-bearing physician networks,...

at 18:28
Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
Illumina, Inc. today announced that it has publicly filed a Form 10 registration statement with the U.S. Securities and Exchange Commission ("SEC"), in connection with its intended divestiture of GRAIL. A version of this registration statement was...

at 18:06
New research confirms that Beethoven had lead poisoning -- but it didn't kill him
To this day, no one knows for certain what caused the liver and kidney disease that led to Ludwig van Beethoven's untimely death. However, a new letter to the editor in the Association for Diagnostics & Laboratory Medicine's (ADLM's, formerly AACC's)...

More news about Health...


News published on and distributed by: